Sheraton Steamboat Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2017


Here are the related meetings in 2018:
Progress and Pathways Toward an Effective HIV Vaccine (J6)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

HIV Vaccines (C9)


Organizer(s) Andrew B. Ward, Penny L. Moore and Robin Shattock
March 26—30, 2017
Sheraton Steamboat Resort • Steamboat Springs, Colorado USA
Discounted Abstract Deadline: Nov 29, 2016
Abstract Deadline: Jan 10, 2017
Scholarship Deadline: Nov 29, 2016
Discounted Registration Deadline: Jan 24, 2017

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Summary of Meeting:
Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, March 26 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 30 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 31 in order to fully experience the meeting.

SUNDAY, MARCH 26

16:00—20:00
Arrival and Registration

Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Foyer

MONDAY, MARCH 27

07:00—08:00
Breakfast

Foyer/Rainbow/Twilight
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Andrew B. Ward, The Scripps Research Institute, USA

Nina Russell, Bill & Melinda Gates Foundation, USA
HIV Vaccines - The Year in Review

09:00—11:30
New Paradigms in Active and Passive Immunization
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Andrew B. Ward, The Scripps Research Institute, USA

Michel C. Nussenzweig, HHMI/Rockefeller University, USA
Passive Protection with 3BNC117

K. Rachael Parks, University of Washington, USA
Short Talk: Optimizing the Expansion of Primary VRC01 Antibody Responses by Germline-Targeting Immunogens

Coffee Break

Todd C. Bradley, Duke University Medical Center, USA
Short Talk: Immune Checkpoint Inhibitor Co-Administration with HIV Env Modifies the Antibody Repertoire

Alejandro Balazs, Massachusetts General Hospital, USA
Development of Vectored ImmunoProphylaxis and ImmunoTherapy against HIV Infection

Jonah B. Sacha, Oregon Health & Science University, USA
Cross-Species CMV Vaccination Reveals Viral Determinants for Induction of Non-Classical MHC-E-Restricted T Cells

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Sunshine/Rainbow/Twilight
13:00—22:00
Poster Viewing

Sunshine/Rainbow/Twilight
14:30—16:30
Workshop 1: Structural and Mechanistic Insights into Neutralization

Storm Peak/Mt. Werner
* Ian A. Wilson, The Scripps Research Institute, USA

Kimmo Rantalainen, The Scripps Research Institute, USA
Structure of Full-Length HIV Envelope in Complex with PGT151

Raiees Andrabi, The Scripps Research Institute, USA
Glycans as Anchors for Inducing HIV Broadly Neutralizing Antibodies

Sasha Murrell, The Scripps Research Institute, USA
Structural Investigation of A Novel Family of Broadly Neutralizing Antibodies that Target the N332 Supersite in HIV Env

Evan M. Cale, NIAID, National Institutes of Health, USA
Isolation of an HIV-1-Specific Neutralizing Antibody Lineage with Similar Characteristics to the gp41-gp120 Interface-Binding Antibody 35O22

Gwo-Yu Chuang, NIAID, National Institutes of Health, USA
Optimization of HIV-1 Broadly Neutralizing Antibodies by Surface-Matrix Scanning

Till Schoofs, Rockefeller University, USA
Antibody 10-1074 Suppresses Viremia in HIV-1 Infected Individuals

Ryan Meyerhoff, Duke University, USA
Induction of Antibodies Targeting the V3 Glycan Broadly Neutralizing Epitope in Rhesus Macaques using a Synthetic Immunogen

16:30—17:00
Coffee Available

Foyer
17:00—19:15
Lessons from Animal Vaccinations
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Rogier W. Sanders, Weill Medical College of Cornell University, USA

Paul Kellam, Kymab, UK
Mice with Fully Human Immunoglobulin Loci and their Use for Predictive Vaccine Antigen Discovery

Maria Blasi, Duke University Medical Center, USA
Short Talk: Sequential Immunizations with an Integrase Defective LentiVector Induce Higher Magnitude and More Durable Antibody Responses than DNA and Protein Based Vaccine Regimens

Nancy L. Haigwood, Oregon Health & Science University, USA
Passive and Active Studies in Primate Models to Inform HIV Vaccines

Peter D. Kwong, NIAID, National Institutes of Health, USA
Short Talk: Peptide-Coupled Carrier Proteins to Focus the Immune Response to an HIV-1 Site of Vulnerability

Andrew B. Ward, The Scripps Research Institute, USA
Structures of HIV Neutralizing Antibodies Elicited from Animal Immunization with SOSIP Env Trimers

19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Foyer/Rainbow/Twilight
19:30—22:00
Poster Session 1

Sunshine/Rainbow/Twilight

TUESDAY, MARCH 28

07:00—08:00
Breakfast

Foyer/Rainbow/Twilight
08:00—11:15
B and T Cells
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Barton F. Haynes, Duke University Medical Center, USA

Gunilla B. Karlsson Hedestam, Karolinska Institutet, Sweden
Individualized Profiling of Germline V Genes and Application to Env Trimer Immunogenicity Studies in NHPs

Thomas B. Kepler, Boston University, USA
B Cell Clonal Dynamics during Sequential Immunizations

Sabrina Helmold, NCI, National Institutes of Health, USA
Short Talk:Dynamics of T Follicular Helper Cells and Germinal Center B Cells over the Course of Vaccination in Rhesus Macaques

Coffee Break

Stephen J. Kent, University of Melbourne, Australia
ADCC and Beyond

Colin Havenar-Daughton, La Jolla Institute of Allergy and Immunology, USA
Short Talk: Germinal Centers Correlate with HIV Trimer-Induced Neutralizing Antibody Induction and Inform Improved Immunization Scheduling for Maximizing HIV Neutralizing Antibody Responses

Marie Pancera, Fred Hutchinson Cancer Research Center, USA
Short Talk: Anti-Idiotypic Antibodies against Inferred Germline b12, a CD4 Binding Site Antibody, as Toosl for Detection of Naïve B Cells Expressing Germline b12-like Precursors and Rational Immunogen Design

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Sunshine/Rainbow/Twilight
11:30—13:00
Hands-On Computer Session on Los Alamos Sequence Database
HIV Database Workshop presented by Los Alamos National Laboratory staff Topics include: • HIV Sequence Database • Bioinformatics tools that have general application Users can register for either or both workshops. Bring your own laptop.

Skyline
13:00—22:00
Poster Viewing

Sunshine/Rainbow/Twilight
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Adjuvants and Delivery Systems
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Robin Shattock, Imperial College London, UK

Carl R. Alving, Walter Reed Army Institute of Research, USA
Rational Basis for Creation and Selection of Adjuvant Formulations for HIV-1 Vaccines

Mark T. Orr, Infectious Disease Research Institute, USA
Tailoring Vaccine Responses with Formulated TLR Agonist Adjuvants

James J. Kobie, University of Rochester, Medical Center, USA
Short Talk: IL-33 Enhances the Induction, Durability, and Breadth of the Antibody Response to a DNA/Protein-Based HIV Env Vaccine

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Regulation of the Germinal Center Reaction and Humoral Response by Vaccine Kinetics

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Foyer/Rainbow/Twilight
19:30—22:00
Poster Session 2

Sunshine/Rainbow/Twilight

WEDNESDAY, MARCH 29

07:00—08:00
Breakfast

Foyer/Rainbow/Twilight
08:00—11:15
Human Clinical Trials
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Gabriella Scarlatti, Global HIV Vaccine Enterprise, USA

Mark B. Feinberg, IAVI International AIDS Vaccine Initiative, USA
Expediting Ebola Vaccine Development and Implications for HIV Vaccine R&D Efforts

Alberto Cagigi, NIAID, National Institutes of Health, USA
Short Talk: Potential for Immunization with eOD-GT8 to Drive B Cell Responses Toward the Production of CD4bs Antibodies

Barton F. Haynes, Duke University Medical Center, USA
Testing the Concept of B Cell Lineage Immunogen Design for Initiation of Broadly Neutralizing B Cell Lineages in Human Clinical Trials

Coffee Break

Kelly E. Seaton, Duke Human Vaccine Institute, USA
Short Talk: Individual-level meta-analysis of HIV-1 Vaccine Elicited Mucosal Antibodies in Human Volunteers

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Induction of HIV-Specific Immunity with Recent Clinical Vaccine Approaches

Robin Shattock, Imperial College London, UK
DNA Vaccination for Experimental Medicine Trials of HIV Vaccines

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Sunshine/Rainbow/Twilight
11:30—13:00
Hands-On Computer Session on Los Alamos Immunology Database
HIV Database Workshop presented by Los Alamos National Laboratory staff Topics include: • HIV Immunology Database • Immunology and vaccine design tools that have general application

Skyline
13:00—22:00
Poster Viewing

Sunshine/Rainbow/Twilight
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Lessons from Infection
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Penny L. Moore, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa

Thumbi Ndung'u, University of KwaZulu-Natal, South Africa
Antiretroviral Treatment of Acute HIV Infection and the Prospect for a Functional Cure

Christiane Moog, INSERM and Université of Strasbourg, France
Short Talk: Unexpected Antibody Isotypes and Neutralizing Profile in Patients Controlling HIV

Julie M. Overbaugh, Fred Hutchinson Cancer Research Center, USA
Unique Aspects of the Infant HIV-Specific Neutralizing Antibody Response

Alexandra Trkola, University of Zürich, Switzerland
Determinants of bnAb Development

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Foyer/Rainbow/Twilight
19:30—22:00
Poster Session 3

Sunshine/Rainbow/Twilight

THURSDAY, MARCH 30

07:00—08:00
Breakfast

Foyer/Rainbow/Twilight
08:00—11:15
Broadly Neutralizing Antibodies: Hurdles and Opportunities
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Alexandra Trkola, University of Zürich, Switzerland

Penny L. Moore, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa
Longitudinal Studies of Neutralizing Antibody Development in the CAPRISA Cohort

Kshitij Wagh, Los Alamos National Laboratory, USA
Short Talk: Env Glycan Holes Negatively Impact Development of Heterologous Neutralization Breadth in HIV-1 Infections

Brandon DeKosky, University of Kansas, USA
Short Talk: High-Throughput Paired Heavy and Light Chain Analyses of HIV Broadly Neutralizing Antibody Lineages

Coffee Break

Elise Landais, International AIDS Vaccine Initiative, USA
Broadly Neutralizing Antibodies to HIV-1: Lessons from Protocol C Studies

Wilton Bryan Williams, Duke University, USA
Short Talk: SHIV-CH505 Infection of Rhesus macaques Recapitulates HIV-1 Env-Antibody Evolution in Humans

Samantha Leigh Grimley, San Diego Biomedical Research Institute, USA
Short Talk: Striking Impact of HIV-1 Envelope Glycoengineering on BnAb Sensitivities

Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Tracing Virus-Antibody Co-Evolution of MPER-directed Neutralizing Antibodies

11:15—17:00
On Own for Lunch

14:30—16:30
Workshop 2: Testing Vaccine Platforms in Animals

Storm Peak/Mt. Werner
* Richard T. Wyatt, IAVI Neutralizing Antibody Center at The Scripps Research Institute, USA

Diane L. Bolton, US Military HIV Research Program, WRAIR, USA
Immunogenicity and Efficacy of MVA, gp145 Vaccination Against Heterologous Tier 2 SHIV C Challenge in Rhesus

Qifeng Han, Duke University, USA
HIV gp41 Immunodominance Following gp140 Immunization Occurs in Humans but is Not Detected in Rhesus Macaques

Mattias Forsell, Umeå University, Sweden
Autologous But Not Heterologous Antibodies Negatively Regulate Subunit-Specific Germinal Center B Cell Responses to the HIV-1 Envelope Glycoproteins

Matthias Pauthner, The Scripps Research Institute, USA
Optimized Env Trimer Immunization Parameters Amplify Onset, Magnitude and Consistency of Autologous Tier 2 Neutralizing Antibody Development in Nonhuman Primates

Paola Andrea Martinez, Karolinska Institutet, Sweden
F9, A New Class of Antibody that Neutralizes Autologous Tier 2 Viruses in Rhesus Immunized with Liposome Conjugated Well-Ordered Trimers

Jose Maximiliano Medina-Ramírez, University of Amsterdam, Netherlands
A Native-Like Envelope Trimer with Enhanced Binding of Inferred Germline Precursors of Broadly Neutralizing HIV-1 Antibodies

James E. Voss, The Scripps Research Institute, USA
Reproducible Elicitation of HIV Envelope V2-Apex Focused Neutralizing Antibodies in Rabbits

16:30—17:00
Coffee Available

Foyer
17:00—18:45
Immunogen Platforms
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
* Peter D. Kwong, NIAID, National Institutes of Health, USA

Jon Steichen, The Scripps Research Institute, USA
HIV Vaccine Design to Target Germline Precursors of N332-Dependent Broadly Neutralizing Antibodies

Neil P. King, University of Washington, USA
Design of Novel Self-Assembling Protein Nanomaterials as Next-Generation Vaccine Scaffolds

Rogier W. Sanders, Weill Medical College of Cornell University, USA
Inducing HIV-1 Neutralizing Antibodies with Native-Like Envelope Trimers

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Storm Peak/Mt. Werner
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Foyer/Rainbow/Twilight
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Sunshine

FRIDAY, MARCH 31

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsor for generously supporting this meeting:

Bill & Melinda Gates Foundation

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI129592-01

“Funding for this conference was made possible [in part] by AI29592-01 from the National Institute of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.”


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Kymab Limited


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676